


New drug mimics benefits of ketamine for depression

April 17 2019, by Bill Hathaway



Chronic depression is marked by loss of synapses and connection between brain cells. A new study shows that the number of dendrite spines increased a day after mice were administered NV-5138, an experimental small molecule drug which mimics the effects of ketamine on depression. The image above shows spine-synapse density in the medial prefrontal cortex before (top) and after NV-5138 treatment (bottom). Credit: Yale University

A new small-molecule drug produced a rapid antidepressant response

similar to that of ketamine when tested in mice, a new Yale-led study published April 16 in the *Journal of Clinical Investigation* shows.

The effects of the [drug](#), called NV-5138, in rodent models mimicked the rapid actions of the [anesthetic ketamine](#), a variation of which, Esketamine, was recently approved by the FDA for use in depressed patients who do not respond to other medications. However, there still remain lingering safety concerns over use of ketamine, as well as Esketamine, both of which have the potential to induce psychosis-like states and also have a potential for abuse.

"Recent research has raised the possibility that a new drug, such as NV-5138, could be developed that is rapid-acting but also more efficacious and safer than current formulations of ketamine," said senior author Ron Duman, the Elizabeth Mears and House Jameson Professor of Psychiatry and professor of neuroscience.

The [experimental drug](#) does not directly stimulate neuronal activity like ketamine, but like ketamine, it spurs the growth of synapses or connections between neurons, the loss of which is associated with chronic stress and depression. The research team also showed that synaptic connectivity markers were rapidly restored in a mouse model of anhedonia, a core symptom of depression marked by an inability to experience pleasure. Mice administered a single dose of the drug also showed marked improvements in other depression-related behaviors.

The drug is being developed by Navitor Pharmaceuticals Inc., which funded the study. It is currently undergoing Phase I testing in human patients.

More information: Taro Kato et al. Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation, *Journal of Clinical Investigation* (2019). [DOI: 10.1172/JCI126859](https://doi.org/10.1172/JCI126859)

Provided by Yale University

Citation: New drug mimics benefits of ketamine for depression (2019, April 17) retrieved 25 April 2024 from

<https://medicalxpress.com/news/2019-04-drug-mimics-benefits-ketamine-depression.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.